Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

OncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 Congress


Posted on: 29 Sep 16

REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present interim data from Phase 1b clinical trials of the company’s Wnt inhibitors, vantictumab and ipafricept, at the upcoming ESMO 2016 Congress being held October 7-11 in Copenhagen, Denmark. 

Vantictumab (anti-Fzd7, OMP-18R5) and ipafricept (FZD8-Fc, OMP-54F28) are each being tested in combination with Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in patients with previously untreated Stage IV pancreatic cancer.  Dr. Colin Weekes of the University of Colorado, an investigator for both Phase 1b clinical trials, will present.

Data from the vantictumab Phase 1b clinical trial will be presented in a poster session on Saturday, October 8 at 1:00 pm CEST:

Abstract #3412; Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
Session: Gastrointestinal Tumors

A poster discussion of data from the ipafricept Phase 1b clinical trial will be presented on Sunday, October 9, 2016 at 3:00 pm CEST:

Abstract #3410 Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) 
Session: Developmental Therapeutics

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR.  OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe.  OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). 

Additional information can be found at the company's website: www.oncomed.com.

Contact:
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals
michelle.corral@oncomed.com
(650) 995-8373

GlobeNewswire
globenewswire.com

Last updated on: 30/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.